On January 9, 2026, AirNexis Therapeutics, a clinical-stage biotech company developing therapeutics for pulmonary diseases, announced the close of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The over-subscribed Series A was led by Frazier Life Sciences, with participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital, and Enavate Sciences, among others. Wilson Sonsini Goodrich & Rosati advised investor SR One on the financing transaction.

Proceeds from the Series A will fund the global clinical development of AN01. Also known as HSK39004, AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors. This MOA may lead to improvements in airflow limitation and airway inflammation, supporting the maintenance treatment of COPD.

The Wilson Sonsini team that advised SR One was led by Dan Koeppen, with support from Kassandra Castillo and Tim Conroy.

For more information, please see AirNexis Therapeutics’ news release. Additional coverage is available in Endpoints News.